Metoprolol to Reduce Perioperative Myocardial Injury

PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 18, 2023

Study Completion Date

August 29, 2023

Conditions
Heart Diseases
Interventions
DRUG

Metoprolol Tartrate

Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).

DRUG

Placebo

Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).

Trial Locations (2)

60637

University of Chicago Medicine, Chicago

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Washington University School of Medicine

OTHER

lead

University of Chicago

OTHER

NCT03138603 - Metoprolol to Reduce Perioperative Myocardial Injury | Biotech Hunter | Biotech Hunter